https://www.selleckchem.com/products/hc-7366.html
Metastatic prostate cancer (CaP) treatments are evolving rapidly but without evidence-based biomarkers to predict responses, and to maximize remissions and survival. To determine the activity of androgen receptor (AR), the target for default first-line systemic treatment, in localized treatment-naïve CaP and its association with clinical risk factors, molecular markers, CaP subtypes, and predictors of treatment response. We examined 452 bona fide AR target genes in clinical-grade expression profiles from 6532 such CaPs collected between
Мне нравится
Комментарий
Перепост
